1. Current status and indications for adjuvant therapy in breast cancer

   • H. J. Senn

   Review Pages: 139 - 150

2. Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology

   • V. Tamassia
   • A. Battaglia
   • G. Robustelli Della Cuna

   Original Articles Pages: 151 - 156

3. Antitumor activity of mitoxantrone against murine experimental tumors: Comparative analysis against various antitumor antibiotics

   • S. Fujimoto
   • M. Ogawa

   Original Articles Pages: 157 - 162

4. Establishment of vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities

   • Bridget T. Hill
   • Richard D. H. Whelan

   Original Articles Pages: 163 - 169

5. Dibromodulcitol plus bleomycin compared with bleomycin alone in head and neck cancer

   • B. F. Issell
   • G. Borsos
   • S. Eckhardt

   Original Articles Pages: 171 - 173

6. In vitro degradation of l-phenylalanine mustard (l-PAM)

   • Thomas L. Evans
   • Sai Y. Chang
   • Klaus Brendel

   Original Articles Pages: 175 - 178

7. Mitoxantrone: A phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours

   • R. C. Stuart-Harris
   • I. E. Smith

   Original Articles Pages: 179 - 182

8. Reduction of lethal toxicity of chloroethylnitrosoureas by sugar alcohols without loss of antitumor activity

   • Tazuko Tashiro
   • Makoto Inaba
   • Yoshio Sakurai

   Original Articles Pages: 183 - 188

9. Pharmacokinetics of mitomycin C in rabbit and human

   • Guy A. van Hazel
   • John S. Kovach

   Original Articles Pages: 189 - 192

10. Accumulation and metabolism of new anthracycline derivatives in the heart after IV injection into mice

    • D. Deprez-de Campeneere
    • R. Baurain
    • A. Trouet

    Original Articles Pages: 193 - 197

11. Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma

    • Philip H. Konits
    • Merrill J. Egorin
    • Peter H. Wiernik

    Original Articles Pages: 199 - 203

12. Relationship of the duration of the chronic phase in chronic granulocytic leukaemia to the need for treatment during the first year after diagnosis

    • Nicholas J. Wareham
    • Stephen A. Johnson
    • John M. Goldman

    Original Articles Pages: 205 - 210

13. Can severe vincristine neurotoxicity be prevented?

    • Z. R. Desai
    • H. W. Van den Berg
    • R. G. Shanks

    Original Articles Pages: 211 - 214

14. The pharmacokinetics of vincristine in man:

    • H. W. Van den Berg
    • Z. R. Desai
    • R. G. Shanks

    Original Articles Pages: 215 - 219

15. Renal handling of 2′-deoxyadenosine and adenosine in humans and mice

    • John F. Kuttesch Jr
    • J. Arly Nelson

    Original Articles Pages: 221 - 229

16. Primary hepatocellular carcinoma

    • Chong-Jin Oon
    • Michael A. Friedman

    Original Articles Pages: 231 - 235

17. The treatment of disseminated non-Hodgkin's lymphoma of unfavourable histology

    • C. J. Gallagher
    • A. Copplestone
    • T. A. Lister

    Original Articles Pages: 237 - 241

18. Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells

    • A. Zenebergh
    • R. Baurain
    • A. Trouet

    Original Articles Pages: 243 - 249

19. Razoxane penetration into the cerebrospinal fluid of rats

    • Nigel Greig
    • Fu Xiao-Chang
    • Kurt Hellmann

    Short Communication Pages: 251 - 252

20. Syndrome of inappropriate ADH secretion secondary to vinblastine

    • Rolf A. Stahel
    • Oswald Oelz

    Letter to the Editor Pages: 253 - 254